| atezolizumab based treatment | pembrolizumab based treatment |
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus carboplatin plus paclitaxel | atezolizumab plus pemetrexed and platin | pembrolizumab and pemetrexed plus platin | pembrolizumab plus SoC |
non squamous cell - mNSCLC - L1 | | | | | | |
non squamous - mNSCLC - L1 - all population 3 | | | | | | |
non squamous - mNSCLC - L1 - PDL1 positive | | | | | | |
non squamous - mNSCLC - L1 - Wild Type (WT) 6 | | | | | | |